Using microRNA to improve testicular cancer management
MicroRNA-371 as Markers for Disease Activity and as a Tool to Monitor the Effect of Chemotherapy and Early Detection of Recurrence in Patients With Testicular Germ Cell Tumours
This study is testing if a specific microRNA can help doctors better detect and manage testicular cancer by identifying active tumor cells in patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 350 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | Male |
| Sponsor | Haukeland University Hospital Academic / other |
| Locations | 6 sites (Bergen and 5 other locations) |
| Trial ID | NCT04914026 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the performance of microRNA-371a-5p (miR371) as a biomarker for detecting viable testicular germ tumor cells in patients with testicular cancer. It will assess the sensitivity and specificity of miR371 during orchiectomy, throughout treatment, and during surveillance for early detection of recurrence. The study involves biomarker analysis to enhance the management of testicular cancer.
Who should consider this trial
Good fit: Ideal candidates include patients aged 18-70 with suspected or diagnosed testicular germ cell cancer who are referred for orchiectomy.
Not a fit: Patients with other prior or concurrent malignancies or conditions that impede their ability to participate will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate detection and monitoring of testicular cancer, improving patient outcomes.
How similar studies have performed: Other studies have shown promise in using biomarkers for cancer detection, but the specific application of miR371 in testicular cancer is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with suspected testicular cancer, referred to orchiectomy. * Patients diagnosed with testicular germ cell cancer. * Age 18-70 years of age. * Must be able receive information and to consent. Exclusion Criteria: * Other prior or concomitant malignancy (other than testicular cancer). * Other diseases or conditions that hinder the ability to receive information and to participate in follow-up procedures.
Where this trial is running
Bergen and 5 other locations
- Haukeland University Hospital — Bergen, Norway (Recruiting)
- Haugesund Hospital — Haugesund, Norway (Recruiting)
- Oslo University Hospital — Oslo, Norway (Not_yet_recruiting)
- University Hospital of North Norway — Tromsø, Norway (Recruiting)
- Sahlgrenska University Hospital — Gothenburg, Sweden (Not_yet_recruiting)
- Karolinska University Hospital — Stockholm, Sweden (Recruiting)
Study contacts
- Principal investigator: Mette Pernille Myklebust, PhD — Haukeland University Hospital
- Study coordinator: Mette Pernille Myklebust, PhD
- Email: mette.pernille.myklebust@helse-bergen.no
- Phone: +47 41684492
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.